Case report: Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy

Takako Goto; Kenichi Miyako; Ryuichi Kuromaru; Kenji Ihara; Hiroyuki Torisu; Masafumi Sanefuji; Rie Nagamatsu; Toshiro Hara

doi:10.1297/cpe.17.71

Case report: Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy

Takako Goto, Kenichi Miyako, Ryuichi Kuromaru, Kenji Ihara, Hiroyuki Torisu, Masafumi Sanefuji, Rie Nagamatsu, Toshiro Hara

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

This report concerns control of adrenocortical carcinoma in a 4-yr-old boy by adjuvant mitotane therapy. He presented precocious puberty and was diagnosed with adrenocortical carcinoma. He underwent surgical resection, and adjuvant mitotane therapy was initiated, leading to a final dose of 5.0 g/day. Despite monitoring of the plasma mitotane level, encephalopathy developed 5 mo after initiation. Although he recovered from the encephalopathy, careful follow-up of his growth and development is necessary. On the other hand, he has been free of recurrence and metastases for 3 yr since discontinuation of mitotane. A high dose of mitotane is potentially effective as an adjuvant chemotherapy for adrenocortical carcinoma, although optimal and safe usage needs to be established for children. Copyright

Original language	English
Pages (from-to)	71-74
Number of pages	4
Journal	Clinical Pediatric Endocrinology
Volume	17
Issue number	3
DOIs	https://doi.org/10.1297/cpe.17.71
Publication status	Published - Jul 2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1297/cpe.17.71

Cite this

@article{9b3d4785944040be983b2bca0b01e846,

title = "Case report: Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy",

abstract = "This report concerns control of adrenocortical carcinoma in a 4-yr-old boy by adjuvant mitotane therapy. He presented precocious puberty and was diagnosed with adrenocortical carcinoma. He underwent surgical resection, and adjuvant mitotane therapy was initiated, leading to a final dose of 5.0 g/day. Despite monitoring of the plasma mitotane level, encephalopathy developed 5 mo after initiation. Although he recovered from the encephalopathy, careful follow-up of his growth and development is necessary. On the other hand, he has been free of recurrence and metastases for 3 yr since discontinuation of mitotane. A high dose of mitotane is potentially effective as an adjuvant chemotherapy for adrenocortical carcinoma, although optimal and safe usage needs to be established for children. Copyright",

author = "Takako Goto and Kenichi Miyako and Ryuichi Kuromaru and Kenji Ihara and Hiroyuki Torisu and Masafumi Sanefuji and Rie Nagamatsu and Toshiro Hara",

year = "2008",

month = jul,

doi = "10.1297/cpe.17.71",

language = "English",

volume = "17",

pages = "71--74",

journal = "Clinical Pediatric Endocrinology",

issn = "0918-5739",

publisher = "Jeff Corporation Co. Ltd",

number = "3",

}

TY - JOUR

T1 - Case report

T2 - Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy

AU - Goto, Takako

AU - Miyako, Kenichi

AU - Kuromaru, Ryuichi

AU - Ihara, Kenji

AU - Torisu, Hiroyuki

AU - Sanefuji, Masafumi

AU - Nagamatsu, Rie

AU - Hara, Toshiro

PY - 2008/7

Y1 - 2008/7

N2 - This report concerns control of adrenocortical carcinoma in a 4-yr-old boy by adjuvant mitotane therapy. He presented precocious puberty and was diagnosed with adrenocortical carcinoma. He underwent surgical resection, and adjuvant mitotane therapy was initiated, leading to a final dose of 5.0 g/day. Despite monitoring of the plasma mitotane level, encephalopathy developed 5 mo after initiation. Although he recovered from the encephalopathy, careful follow-up of his growth and development is necessary. On the other hand, he has been free of recurrence and metastases for 3 yr since discontinuation of mitotane. A high dose of mitotane is potentially effective as an adjuvant chemotherapy for adrenocortical carcinoma, although optimal and safe usage needs to be established for children. Copyright

AB - This report concerns control of adrenocortical carcinoma in a 4-yr-old boy by adjuvant mitotane therapy. He presented precocious puberty and was diagnosed with adrenocortical carcinoma. He underwent surgical resection, and adjuvant mitotane therapy was initiated, leading to a final dose of 5.0 g/day. Despite monitoring of the plasma mitotane level, encephalopathy developed 5 mo after initiation. Although he recovered from the encephalopathy, careful follow-up of his growth and development is necessary. On the other hand, he has been free of recurrence and metastases for 3 yr since discontinuation of mitotane. A high dose of mitotane is potentially effective as an adjuvant chemotherapy for adrenocortical carcinoma, although optimal and safe usage needs to be established for children. Copyright

UR - http://www.scopus.com/inward/record.url?scp=49449105356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449105356&partnerID=8YFLogxK

U2 - 10.1297/cpe.17.71

DO - 10.1297/cpe.17.71

M3 - Article

AN - SCOPUS:49449105356

SN - 0918-5739

VL - 17

SP - 71

EP - 74

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

IS - 3

ER -

Case report: Adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this